Key Details
Price
$6.91PE Ratio
24.68Annual ROE
3.94%Beta
0.81Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 6, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Aug 25, 2010Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Call Start: 08:30 January 1, 0000 9:52 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q3 2024 Earnings Conference Call November 13, 2024, 08:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to the Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.
Kamada Ltd. (NASDAQ:KMDA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Troy Williams - LifeSci Advisors Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Greetings, and welcome to Kamada Limited Second Quarter 2024 Earnings Conference Call.
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET
Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-rabies drug Kedrab including a minimum revenue guarantee for the next four years. The new deal significantly derisks the Kamada investment case by locking in growth for one of the company's largest revenue streams.
Kamada Ltd. has potential catalysts for growth, capital attraction and regulatory tailwinds. The company's valuation appears attractive, with forward estimates suggesting a possible re-rating. Key risks center around the investment in 2x new manufacturing facilities in its Israeli footprint.
Kamada Ltd. (NASDAQ:KMDA ) Q1 2023 Results Earnings Conference Call May 24, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Chief Executive Officer Conference Call Participants David Bautz - Zacks Small Cap Research Operator Greetings and welcome to the Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023.
FAQ
- What is the ticker symbol for Kamada?
- Does Kamada pay dividends?
- What sector is Kamada in?
- What industry is Kamada in?
- What country is Kamada based in?
- When did Kamada go public?
- Is Kamada in the S&P 500?
- Is Kamada in the NASDAQ 100?
- Is Kamada in the Dow Jones?
- When was Kamada's last earnings report?
- When does Kamada report earnings?
- Should I buy Kamada stock now?